The Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation to Autolus ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted ...

Autolus Therapeutics plc (Nasdaq: AUTL), an early commercial-stage biopharmaceutical company developing, manufacturing and delivering next-generation programmed T cell therapies, today presented ...

Autolus Therapeutics, a UCL spinout company, has received authorisation from the UK Medicines and Healthcare products ...

Autolus Therapeutics plc (AUTL)’s share was trading at $3.20 as of Dec 3rd. Autolus Therapeutics is a biopharmaceutical company focused on developing innovative CAR-T cell therapies for the ...

Autolus Therapeutics plc, a biopharmaceutical company focused on next-generation programmed T cell therapies, has announced the upcoming release of its first quarter 2025 financial results and ...

View Our Latest Report on Autolus Therapeutics Autolus Therapeutics Stock Up 4.5 % AUTL opened at $1.39 on Tuesday. The stock has a market capitalization of $369.87 million, a price-to-earnings ...

Autolus Therapeutics plc announced that the UK Medicines and Healthcare products Regulatory Agency (MHRA) has granted conditional marketing authorisation for AUCATZYL (obecabtagene autoleucel ...

Company outlined potential for value creation driven by obe-cel across multiple B cell driven malignancies and autoimmune diseases, including acute lymphoblastic leukemia (ALL), lupus nephritis (LN) ...

Autolus Therapeutics (AUTL) confirmed that the U.K. Medicines and Healthcare products Regulatory Agency has granted conditional marketing authorization for AUCATZYL for the treatment of adult ...